Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

@article{Shimamura2013EfficacyOB,
  title={Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.},
  author={Takeshi Shimamura and Zhao Chen and Margaret Soucheray and Juli{\'a}n Carretero and Eiki Kikuchi and Jeremy H. Tchaicha and Yandi Gao and Katherine A. Cheng and Travis J. Cohoon and Jun Qi and Esra A. Akbay and Alec C. Kimmelman and Andrew L Kung and James E. Bradner and Kwok-kin Wong},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 22},
  pages={6183-92}
}
PURPOSE Amplification of MYC is one of the most common genetic alterations in lung cancer, contributing to a myriad of phenotypes associated with growth, invasion, and drug resistance. Murine genetics has established both the centrality of somatic alterations of Kras in lung cancer, as well as the dependency of mutant Kras tumors on MYC function. Unfortunately, drug-like small-molecule inhibitors of KRAS and MYC have yet to be realized. The recent discovery, in hematologic malignancies, that… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2018
View 17 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Clinicopathologic features and long-term outcomes of NUT midline carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…